Wolfgang Miesbach, MD

Professor and Head of Coagulation Disorders and Comprehensive Care Centre
University Hospital Frankfurt, Frankfurt, Germany
Frankfurt, Hessen, Germany

Prof. Dr. med. Miesbach is head of the Department of Coagulation Disorders and the Comprehensive Care Haemophilia Centre at the Goethe University Hospital in Frankfurt/Main, Germany. In addition, he is head of the ISTH SSC Working group on Gene Therapy and the EAHAD Gene Therapy Working Group. His main research interest is in the field of hemophilia with focus on GT and quality of life investigations.

Presentation(s):

• LB 01.2 - Emicizumab prophylaxis instead of immunosuppressive therapy in patients with acquired hemophilia A (AHA)

  Sunday, June 25, 2023
  11:00 – 11:15 ET

• OC 20.5 - The WFH Gene Therapy Registry: A Collaborative Approach Towards a Global Resource for the Long-term Follow-up of People with Hemophilia Treated with Gene Therapy

  Sunday, June 25, 2023
  15:45 – 16:00 ET

• SSC 12.1 - Session Welcome

  Sunday, June 25, 2023
  16:30 – 16:35 ET

• SSC 12.9 - Question/Answer Session

  Sunday, June 25, 2023
  17:50 – 18:00 ET

• SSC 12.11 - Question/Answer Session

  Sunday, June 25, 2023
  18:10 – 18:25 ET

• SSC 12.12 - Session Conclusion

  Sunday, June 25, 2023
  18:25 – 18:30 ET

• PB0191 - myGTR: a patient engagement tool from the World Federation of Hemophilia Gene Therapy Registry

  Sunday, June 25, 2023
  18:30 – 19:30 ET

• PB0643 - Efficacy of emicizumab prophylaxis in patients with severe hemophilia A in Germany: Follow-up evaluation of real-life-data documented by smart medication eDiary

  Monday, June 26, 2023
  18:30 – 19:30 ET

• PB0670 - Nationwide survey on the care reality of people with mild hemophilia A and B in Germany - The Burden of mild Hemophilia

  Monday, June 26, 2023
  18:30 – 19:30 ET

• PB0693 - Efficacy and Safety of Eptacog Beta (Recombinant Activated FVII) in Patients with Hemophilia A or B with Inhibitors According to Time to Initial Infusion: a Post-Hoc Analysis from PERSEPT-1

  Monday, June 26, 2023
  18:30 – 19:30 ET

• OC 52.1 - Assessing the safety profile of AMT-060 and etranacogene dezaparvovec gene therapies across clinical trials in people with severe/moderately severe hemophilia B

  Tuesday, June 27, 2023
  10:45 – 11:00 ET

• OC 52.5 - Phase 3 HOPE-B trial of etranacogene dezaparvovec in severe/moderately severe hemophilia B: A post hoc responder analysis of participants who received full dose and responded to treatment

  Tuesday, June 27, 2023
  11:45 – 12:00 ET